Drug intelligence / Profile preview

manfidokimab

Development stage: Phase 3
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Manfidokimab (AK120) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that targets the interleukin-4 receptor alpha subunit (IL-4Rα), a component shared by both the IL-4 and IL-13 receptors. By binding to IL-4Rα, it blocks signaling from both cytokines, thereby inhibiting the Th2 inflammatory pathway implicated in atopic dermatitis and other type 2 inflammatory diseases. Manfidokimab is being developed primarily for moderate-to-severe atopic dermatitis and has also been investigated for asthma and eosinophilic esophagitis. The drug has shown acceptable safety and preliminary efficacy in clinical trials[2][3][6].

Other names: manfidokimab

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on manfidokimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on manfidokimab.